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A B S T R A C T   
Following cancer, cells in a particular tissue can no longer respond to the factors involved in controlling cell 
survival, differentiation, proliferation, and death. In recent years, it has been indicated that alterations in the gut 
microbiota components, intestinal epithelium, and host immune system are associated with cancer incidence. 
Also, it has been demonstrated that the short-chain fatty acids (SCFAs) generated by gut microbiota are vitally 
crucial in cell homeostasis as they contribute to the modulation of histone deacetylases (HDACs), resulting 
effected cell attachment, immune cell immigration, cytokine production, chemotaxis, and the programmed cell 
death. Therefore, the manipulation of SCFA levels in the intestinal tract by alterations in the microbiota structure 
can be potentially taken into consideration for cancer treatment/prevention. In the current study, we will explain 
the most recent findings on the detrimental or protective roles of SFCA (particularly butyrate, propionate, and 
acetate) in several cancers, including bladder, colon, breast, stomach, liver, lung, pancreas, and prostate cancers.   
1. Introduction 
Cancer is commonly known to be caused by an interaction between 
environmental factors and the genetics of the host [1]. In addition to 
genetic determinants, many studies have indicated the pivotal role of 
microorganisms in cancer biology [1]. Several carcinogenic pathogens 
including, hepatitis C (HCV) and B (HBV) viruses, Helicobacter pylori, 
and human papillomaviruses (HPV), have been observed in about 20% 
of all cancers [2]. Accordingly, additional oncogenic microorganisms 
may be present with a synergic function to start or develop tumorigen-
esis. This microbial population, known as the microbiota, has been 
recently identified as essential factors in cancer biology [1]. In recent 
years, state-of-the-art technologies have been developed to analyze the 
human microbiota to quantify the microbiome community members and 
determine their role in cancer development [3]. 
Despite various investigations on the association between gut 
microbiota and cancer, the exact mechanisms of this interplay are not 
thoroughly investigated. However, it has been demonstrated that this 
interaction may be subsequent to bacterial metabolites [4]. Gut micro-
biota generates numerous short-chain fatty acids (SCFAs) from 
non-digestible and fermentable carbohydrates, including dietary fiber 
[5]. Main SCFAs with total intestinal concentration exceeding 100 mM 
include propionate, acetate, and butyrate [6]. Recently, it has been 
indicated that SCFAs can affect the progress of various diseases, such as 
inflammatory bowel disease (IBD), diabetes, atherosclerosis, and colo-
rectal cancer (CRC) [7–9]. Researchers have predominantly focused on 
the effect of SCFAs on CRC [10,11]. Investigations have shown that the 
fecal SCFA levels declined in CRC patients compared to the control 
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following the decreased number of SCFAs-producing bacteria [12,13]. 
It has been found that several bacteria could generate tumor- 
boosting metabolites such as secondary bile acids, whereas some bac-
teria could secrete tumor-suppressing metabolites like SCFAs [14,15]. 
Based on the significance of SCFAs, substantial epidemiological data 
established that an enhanced rate of inflammatory disorders and cancer 
was mediated to subjects with diets poor in SCFAs or diminished amount 
of fecal SCFAs, particularly for breast as gastric cancers [16]. SCFAs in 
the host gut and other parts could extensively diminish carcinogenesis 
and prevent and treat gastrointestinal and lung cancers by inhibiting cell 
growth and migration, suppressing histone deacetylases (HDAC), and 
inducing apoptosis [17]. Additionally, epidemiological investigations 
have found that high-fiber diets are mediated to a low incidence of 
cancer compared to red meat consumptions, which have been noted to 
enhance cancer risk [18–20]. Currently, it has also been found that the 
key for high fiber diets to exert anti-cancer influences is the formation of 
SCFAs like butyrate via the action of the microbiota [15]. Here, we will 
discuss the current evidence from the most recent studies on the asso-
ciation between SCFAs generated from gut microbial population and 
selected cancers. 
2. The production and metabolism of microbiota-derived SCFAs 
2.1. Microbiota in the gastrointestinal tract 
Our lifestyle, including exercise, diet, microbial exposure during 
childhood, and antibiotic treatment, can markedly affect our microbiota 
[21]. Two bacterial phyla that prevail in the human gut are Bacteroidetes 
and Firmicutes [21]. Over the recent decades, different technologies for 
bacterial classification to specific genus and species have resulted in 
various reclassifications [21]. Bacterial species can be further classified 
into subspecies according to trivial but relevant alterations within a 
species [21]. Based on different immune antigens on the bacterial sur-
face, further classifications into strains or serovars are specified outside 
nomenclature rules [21]. This level of complexity explains the aim of 
determining microbial metabolites within the gut community, thereby 
preventing the complications of bacterial species while focusing on their 
metabolism [21]. Epidemiological studies have demonstrated an asso-
ciation between bacterial colonization and cancer progression [21]. 
However, determining the function of bacterial cells in cancer devel-
opment is difficult owing to the impact of host determinants in cancer 
susceptibility, the ubiquitous nature of bacteria, and the prolonged 
period of overt cancer development following the introduction of bac-
terial cells [22]. This can be complicated by environmental factors with 
more significant roles in determining one’s microbiota structure than 
genetic factors [23]. While data on bacterial interaction with human 
cells is rapidly increasing, there is a great potential for further innova-
tion when considering other microbes (viruses and fungi) that reside in 
the gastrointestinal tract [24]. 
2.2. Microbiota and short-chain fatty acids formation 
Members of the gut microbiota produce several SCFAs from dietary 
fiber [4]. Propionate, acetate, and butyrate belong to SCFAs, and their 
total intestinal concentration may exceed 100 mM [6]. Most SCFAs are 
the final product of bacterial fermentation, and endogenous host syn-
thesis is usually trivial (Fig. 4) [25]. SCFAs are produced by two major 
bacterial groups: propionate and acetate are formed by Bacteroidetes, 
while butyrate is produced by Firmicutes [26]. SCFAs are important 
players in the interaction between the host and gut microbiota [4]. 
SCFAs can affect the colon and other organs via blood flow: the uptake of 
SCFAs following fasting can contribute to elevated serum acetate levels 
[4]. Recent studies have indicated that SCFAs could affect the progres-
sion of different diseases, like IBD, diabetes, atherosclerosis, and CRC [4, 
7–9]. Many studies have particularly focused on CRC [11]. Based on 
clinical case studies, fecal SCFAs levels declined in CRC patients 
compared to the control groups, which can be attributed to the reduced 
number of SCFAs-producing organisms, including Lachnospiraceae, 
Roseburia spp., Bifidobacterium spp. [12,13]. 
3. The interaction between intestinal barrier function, 
inflammation, and carcinogenesis 
3.1. Inflammation, microbiota, and carcinogenesis 
Following disturbance of normal microbiota and immune cells, 
including interleukins (ILs), transforming growth factor-beta (TGF-β), 
vascular endothelial growth factor (VEGF), and tumor necrosis factor 
(TNF) are released [27]. While pattern recognition receptors (PRRs) are 
involved in reinforcing cellular junctions to support the epithelial bar-
rier, the proinflammatory cytokines increase mucosal permeability of 
the paracellular routes for microbe entry [27]. Both growth factors and 
cytokines induce inflammation, which negatively impacts differentia-
tion by maintaining the survival and growth of dysplastic cells [27]. 
Tumor and bacterial cells may produce large amounts of cytokines in a 
self-maintaining manner [28]. In case inflammation persists, the 
continued propagated inflammatory signals, hindered apoptosis, and 
elevated levels of growth factors all contribute to cancer development 
[29]. 
In many diseases that microbiota involve in progression, it has been 
found that disruption of the epithelial layers results in microorganisms 
and their metabolites reaching compartments that are not usually in 
close contact with microorganisms [30]. This situation could induce 
local chronic inflammatory reactions because of prolonged injured tis-
sue and, hence, a constant stream of infiltrating microorganisms and 
their metabolites. For instance, in CRC and IBD, the underlying mucosal 
layers are interrupted, exposing the deep sections and resident immune 
components to further rates of microorganisms and their metabolites 
[30,31]. This situation accelerates tumor progression via 
pro-tumorigenic factors such as chemokines and cytokines that could act 
as growth factors that some activates like the stimulation of migration 
and enhance the angiogenesis. It has currently been found that 
commensal bacteria stimulate the Interleukin 6 (IL-6), Interleukin 17 
(IL-17), Interleukin 22 (IL-22), and Interleukin 23(IL-23) signaling in 
colon adenoma models because of defects in integrity of colon barrier, 
and antibacterial drug therapy, as well as genetic ablation of IL-23, 
abrogates tumorigenesis [32]. 
Along with microbiota dysbiosis, pathogenic bacteria have a crucial 
activity in some diseases such as CRC [30]. In this regard, various bac-
teria were noted to trigger CRC, such as certain strains of Helicobacter 
pylori, Escherichia coli, Bacteroides fragilis, Streptococcus gallolyticus, 
Enterococcus spp, and some member of Enterobacteriaceae [30,33,34]. 
These bacteria can bind to the target tissue’s epithelial layers and 
directly stimulate the growth and proliferation of epithelial cells, 
resulting in hyperplasia. Besides, these bacteria could generate toxins 
that cause epithelial barrier integrity disruption, as well as 
inflammation. 
Different cytokines may be used as biomarkers in therapy [27]. A 
classification system (Immunoscore®) may be used for improving the 
prognosis of CRC [27]. According to several studies, the Immunoscore 
was more efficient in determining microsatellite instability for survival 
prognosis [35–37]. Following the interruption of eubiosis, IL-6, TGF-β, 
and TNF generated by T cells and macrophages leading to the differ-
entiation of naive CD4 T cells into pro-inflammatory T helper 17 (Th17) 
cells which play a significant role in the adaptive immune response 
against pathogens [27,38,39]. Following persistent inflammation of the 
mucosa, the continued presence of Th17 is associated with CRC pro-
gression. Th17 infiltration to CRC tissue and increased concentrations of 
IL-22 and IL-17 are linked with declined survival rate [40,41]. Inter-
estingly, several microbiota members, particularly Clostridia species, 
and dysplasia promote the production of Th17 and IL-17 in epithelial 
cells. Th17 has also been indicated as an essential factor in CRC in 
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murine models exposed to Enterotoxigenic Bacteroides fragilis (ETBF) 
[27]. Reduced microadenoma has been noted by the restriction of Th17 
following T-regs depletion [42,43]. 
Furthermore, tumors with increased infiltration of CD3+ (and 
probably CD8+) are linked with improved survival [44]. IL-6 is a potent 
proinflammatory cytokine that seems to be associated with angiogenesis 
and CRC progression [27]. IL-6 formed by T cells, macrophages, and 
fibroblasts of the tumor-supporting stroma can trigger signal transducer 
and activator of transcription 3 (STAT3), contributing to tumor pro-
gression. In CRC patients, increased serum IL-6 levels could be consid-
ered as a prognostic biomarker for tumor mass, metastases, and low 
survival [45,46]. TGF-β generated by macrophages and inflammatory 
cells, is essential in cell differentiation, growth, and programmed cell 
death. In normal conditions, cell growth is prevented following the 
activation of TGF-β in epithelial cells, while mutations in TGF-β 
signaling and receptors have been significantly found in CRC [47,48]. 
TGF-β formed by tumor stromal fibroblasts has a contradictory impact 
and induces the growth and propagation of CRC cells [27]. Elevated 
TGF-β production increases the risks of tumor recurrence following 
treatment due to increasing the survival rate of metastatic cells [49]. 
TNF produced by macrophages also contributes to the recruitment of 
inflammatory cells, increased mitogenic signaling, and vascular 
permeability [27]. TNF induces oncogenic signaling pathways such as 
the Wnt and Nuclear factor-kappa B (NF-κB) in epithelial cells, thereby 
controlling cell survival and growth [27]. When epithelial cells are 
exposed to TNF, CIS and mutation frequencies increase, implying the 
direct contribution of TNF to cancer progression [50–53]. Serum levels 
of TNF have been linked with disease advancement and low survival 
rates in CRC patients [54,55]. Serum levels of TNF have been linked with 
disease advancement and low survival rates in CRC patients [54,55]. 
Also, potential pathophysiological routes of inflammation are comprised 
of the oxidative stress stimulated by an imbalance between the gener-
ation of reactive oxygen species (ROS) and antioxidant protection after 
DNA disruption and dysplasia, which support tumor progression [27]. 
Oxidative stress increases tumor-promoting or pro-inflammatory cyto-
kines and anti-apoptotic signaling by NF-κB, thereby linking chronic 
inflammation to cancer [27]. NF-κB can direct several genes (including 
Bcl-x and surviving), thereby enhancing tumor cell proliferation and 
hindering apoptosis [28,56]. Of note, obesity induces the expression of 
NF-κB in most tissues and increases the risk of type-2 diabetes [27]. 
NF-κB could link type 2 diabetes, obesity, IBD, and cardiovascular dis-
ease with cancer [57,58]. 
Interestingly, several microbiota members, particularly Clostridia 
species, promote Th17 and IL-17 in epithelial cells. Th17 has also been 
indicated as an important factor in CRC in murine models exposed to 
Enterotoxigenic B. fragilis (ETBF) [27]. Reduced microadenoma has 
been noted by the restriction of Th17 following T-regs depletion [42, 
43]. 
4. The mechanism of short-chain fatty acids in cells 
SCFAs show both extracellular and intracellular outcomes by being 
Fig. 1. Mechanisms of signaling from short-chain fatty acid derived from bacteria in gut immune cells. Short-chain fatty acids (propionate, butyrate, and acetate) 
involve in a complexed host-microbiome interaction to intestinal immune reactions (for example development of Regulatory T cells (Tregs), the activity of Dendritic 
cell (DC) and macrophage, and the anti-inflammatory cytokines production, proliferation of plasma B cell, as well as production of antibody) by inhibition of histone 
deacetylase (HDAC) and activation of GPR109A and GPR43, finally exerting anti-inflammatory impacts and conferring tolerance toward microbial pathogens. 
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ligands to their receptors and functioning as epigenetic regulators, 
respectively (Fig. 1) [59]. Receptors of SCFAs are present throughout the 
human body [59]. These receptors belong to G-protein coupled re-
ceptors (GPCRs), suggesting their role in several cellular pathways [59]. 
GPR109A is a surface receptor of adipocytes, colonocytes, and macro-
phages [60]. This receptor in adipocytes is commonly involved in 
releasing fat stores in deprivation conditions [61]. The reduced 
expression of GPR109A can also lead to CRC progression [60]. Report-
edly, GPR109A contributes to the differentiation of T reg cells and the 
formation of both anti-inflammatory (IL-10) and proinflammatory 
(IL-18) cytokines [60]. These responses have been associated with 
carcinogenic outcomes, as shown in Niacr1-/- mice [62]. Moreover, cell 
cycle regulation and apoptosis can be affected by SCFAs [4]. GPR41/43 
activation promotes the intracellular levels of Ca2+ and promotes the 
stimulation of mitogen-activated protein kinases (MAPK) p38 in MCF-7 
cells [4]. These results are widely linked with cellular stress responses 
and even carcinogenesis [63,64]. Also, GPR43 is not present in meta-
static cells and colon tumors, suggesting its role in carcinogenesis. 
G0/G1 cell cycle arrest and apoptosis have been occurring following the 
restored expression of GPR43 in adenocarcinoma cell lines [65]. 
A possible association between SCFAs and cancer may be owing to 
the stimulation of GPCRs [4], which can trigger the cascades of re-
sponses that either leads to malignancy or hinder it (Fig. 2) [4]. SCFAs 
may act as ligands to membrane receptors, thereby affecting cell meta-
bolism [4]. Butyrate may employ sodium-coupled monocarboxylate 
transporter (SMCT1) for cell entry. This transporter was first charac-
terized as a potential tumor suppressor [4,66]. Butyrate can also use 
other transporters to circulate inside the body [4]. One of the main 
carriers is the MCT4 (monocarboxylate transporter 4), which fluxes 
butyrate to the blood flow [67], allowing butyrate to demonstrate a 
systemic impact on the host organism within the bloodstream [4]. 
Butyrate can enter back to the intestinal lumen with BCRP (breast cancer 
resistance protein) [4]. The reduced mRNA expression of BCRP is 
possibly linked with colorectal adenoma progression, which might be 
associated with butyrate accumulation within cells [68]. 
Following cell entry, butyrate can affect histone deacetylases 
(HDACs) [4]. These enzymes are primarily involved in cell cycle regu-
lation, proliferation, and programmed cell death [69]. Butyrate and its 
binding to HDACs have been associated with CRC development [70,71]. 
Following the binding of butyrate to HDACs, its enzymatic activity is 
hindered, leading to histone hyperacetylation and altered gene expres-
sion [4]. Finally, butyrate can suppress the growth of tumor cells by 
Fig. 2. Impacts of the short-chain fatty acids (SCFAs) on the function of immune cells. A) The enhanced rate of butyrate suppresses the activity of histone deacetylase 
(HDAC) and stimulates apoptosis, reduces growth, and prompts immunogenicity of the cancer cell. B) In the human normal epithelial cell, butyrate is metabolized via 
OXPHOS (oxidative phosphorylation) and applied by the cell for the source of energy. C) Additionally, butyrate activates NLRP3 (NOD-, LRR- and pyrin domain- 
containing protein 3) inflammasomes via binding to G-protein-coupled receptors (GPRs), cause the expression of Interleukin 1 beta (IL-1β) and Interleukin-18 
(IL-18). On the other hand, IL-18 promotes the diversity of intestinal bacteria and strengthens the intestinal barrier integrity. The impacts of butyrate on human 
immune cells in the lamina propria could be defined as promoting the role of anti-inflammatory factors, like Regulatory T cells (Tregs) while inhibiting function 
immune cells involving in inflammation, for example, butyrate inhibits the Dendritic cell (DC) maturation, limit its potential to prime Cytotoxic T lymphocyte (CTL) 
and diminishes the pro-inflammatory cytokine formation of in macrophages and DC that, overall, diminishes inflammation and the development of T-helper cell 17 
(Th17) that involve in carcinogenesis in intestinal cells. 
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activation of cell cycle arrest and apoptosis [4]. Butyrate could affect 
other processes involved in epigenetic regulation, including histone 
phosphorylation and methylation, DNA methylation, and hyper-
acetylation of nonhistone proteins [4,72,73]. 
5. The effects of short-chain fatty acids in cancer 
5.1. Colorectal cancer 
CRC is the third most prevalent fatal cancer in the world [74,75]. 
Diet is one of the most critical determinants involved in CRC progression 
[76,77]. Among SCFAs, butyrate is a significant metabolite that medi-
ates CRC suppression through dietary fiber [76]. Unlike other SCFAs, 
butyrate is mainly metabolized by colonocytes cells and is involved in 
epigenetic modifications, where it elevates the rate of histone acetyla-
tion by blocking histone deacetylases [76,78]. At proper concentrations, 
butyrate increases differentiation reduces proliferation, and induces 
programmed cell death in CRC cells [70,76]. Of note, the effect of 
butyrate on cell apoptosis and proliferation is attributed to its colono-
cyte metabolism [79,80]. Many studies have indicated that colonocytes 
are involved in the beta-oxidation of butyrate, which can be affected by 
exogenous agents [81,82]. Moreover, the proliferation of cancerous 
colonocytes reduces following exposure to butyrate, while that of 
non-cancerous colonocytes increases [76]. Therefore, butyrate has 
various effects on both cancerous and non-cancerous colonocytes with 
different metabolic traits. 
Interestingly, Ohara et al. [83] noted that enhanced CRC risk linked 
tightly to the changed gut microbiota, the diminished concentration of 
SCFAs, and further inflammation situation. Besides, in a systematic and 
meta-analysis study by McLoughlin et al. [84], they examined the evi-
dence for the effect of SCFAs, prebiotics, and synbiotics on systemic 
inflammation in healthy populations, diabetes, overweight, and obesity, 
kidney disease, cancer, liver disease, and bowel diseases. They found 
half of the included studies noted a significant diminish in ≥ 1 systemic 
inflammatory biomarker, and meta-analyses showed that prebiotic and 
synbiotic supplementation are mediated to diminished systemic in-
flammations such as TNF-α, C-reactive protein (CRP), and IL-6, although 
the association was stronger with certain supplement types (particularly 
oligosaccharides) [84]. Additionally, Nomura et al. [85] evaluated fecal 
and plasma SCFAs in patients with solid cancers treated with pro-
grammed cell death-1 inhibitors (PD-1i). They found that fecal SCFA 
rates can be related to PD-1i efficacy; hence, SCFAs can link the gut 
microbiota and PD-1i efficacy. Because fecal examinations are nonin-
vasive, they can be applied for routine monitoring of patients, thus, 
enhancing SCFAs formation through regulation of gut microbiota should 
have a bright future in anti-cancer therapy. Besides, in a systematic re-
view and dose-response meta-analysis of prospective studies, Aune et al. 
[86] surveyed dietary fiber, whole grains, and risk of colorectal cancer. 
Additionally, many epidemiologic studies support the role of dietary 
fiber in the protection against colorectal cancer and, in this regard, 
various mechanisms have been noted for fiber’s cancer-preventive 
properties including a reduction in transit time of the feces in the gut 
that diminishes exposure of the mucosa to luminal carcinogens, ab-
sorption of biogenic amines, bile acids, bacterial toxins, as well as the 
formation of SCFAs like butyrate [87–107]. 
Over the past few decades, it has been demonstrated that the gut 
microbiome, which could be influenced by diet, is essential in CRC 
initiation [108]. After digestion and absorption, different foods leave 
residues in the digestive tract [108]. As food moves throughout the 
colon, gut microbiota ferments the residues of dietary fiber to generate 
SCFAs, affecting intestinal epithelial cells and gut microbiota [97,109]. 
Research has indicated butyrate as the primary energy source of the 
intestinal epithelial cells, rather than glucose, establishing the basis for 
the notion of mutualism between intestinal epithelial cells and gut 
microbiota [110]. Butyrate could impede CRC progression and improve 
intestinal health by several mechanisms [108]. 
Butyrate has anti-tumor and anti-inflammatory traits and can be an 
energy source for intestinal epithelial cells [108]. A recent mechanism 
proposed for the impact of butyrate molecule on CRC development is the 
reduced expression of butyrate transporter protein in cancerous tissue 
and the subsequent reduced intestinal butyrate transport and meta-
bolism (Fig. 3) [111]. The impairment of butyrate metabolism has been 
linked with different colonic disorders [112]. Currently, it has been well 
established that the pathogenesis of CRC is associated with the disrup-
tion of the intestinal epithelial barrier, which leads to the stimulation of 
tumor-related macrophages, generation of inflammatory cytokines, and 
tumor development [113]. Butyrate could enhance the assembly of the 
tight junction by stimulating the AMPK (Amp-activated protein kinase) 
[113]. It can maintain the intestinal epithelial barrier’s function by 
triggering the expression of MUC2 in LS174T (the human colon cancer 
cell line) [114–116]. It can also reduce the movement of the gastroin-
testinal tract, thereby reducing the rate of intestinal transport and 
affecting the incidence of CRC [108]. According to different studies, 
butyrate can affect the internal nervous system and modulate the 
excitability of neurons, leading to the reinforced extracorporeal 
contraction action [117,118]. 
Hence, butyrate is pivotal for maintaining the balance of intestinal 
microbiota balance and colon health. Also, different works have 
demonstrated that butyrate could hinder the occurrence and progression 
of CRC by different mechanisms [108]. Conversion of butyrate to 
acetyl-CoA occurs through beta-oxidation, which is then totally oxidized 
the Krebs cycle [108]. This conversion is crucial for inducing the 
enzymatic role of histone acetyltransferase [108]. Owing to the Warburg 
effect, butyrate is not usually metabolized in cancer cells. Yet, it could be 
accumulated as an HDAC inhibitor (HDACi) in the nucleus and subse-
quently modulates downstream target gene expression [108]. HDAC 
enzymes are crucial for gene expression, and their expression in tumor 
cells varies in different tumor types [79]. For instance, HDAC1 is present 
mainly in gastric cancer, prostate cancer, breast cancer, lung cancer, and 
esophageal cancer, while HDAC2 is present primarily in cervical cancer, 
colorectal cancer, and gastric cancer [108] (Fig. 4). 
Furthermore, HDAC3 is present mainly in colorectal cancer and 
breast cancer, whereas HDAC6 is present mainly in neuroblastomas 
[119,120]. In most tumors, acetylation will lead to the altered expres-
sion of several genes that mediate various signaling pathways, including 
extracellular-signal-regulated kinase (ERK) and Wnt, and further in-
fluences the protease system and the functions of several enzymes such 
as protein kinase C [121]. HDACi can lead to cell death through various 
processes such as alterations in histone modifications, gene expression, 
and epigenetic alterations [122]. Following the blockade of histone 
acetylation, chromatin lysis occurs, leading to better exposure of DNA 
[108]. The reduced activity of HDAC has been linked with the hindrance 
of tumor cell progression [123]. Butyrate has different functions in 
histone acetylation and can affect the progression of tumor cells by the 
activation of the cell cycle arrest and programmed cell death. 
5.2. Bladder cancer 
Bladder cancer is the ninth most common malignancy, with more 
than 160,000 deaths annually worldwide [124]. The risk of developing 
this disorder increases with age, and it occurs three times more often in 
male populations [124]. As most cases are > 65 years old and owing to 
the rise in life expectancy, it is estimated that the prevalence of patients 
with this disorder will increase shortly [125]. In addition to environ-
mental and genetic factors, studies have shown that microbiota is vitally 
important in maintaining health and preventing the occurrence of 
various diseases [124]. Using DNA-based techniques, studies have 
indicated that disturbance in microbiota is linked with different disor-
ders [124]. 
SCFAs might be involved in hindering pathological conditions like 
cancer and IBD for their anti-inflammatory, immune-modulatory, and 
anti-neoplastic traits. Besides, butyric acid exerts a direct inhibitory 
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impact on bladder cancer cells by preventing cell growth and activating 
programmed cell death in vitro [126]. Although various studies indicate 
that the intake of fruits and vegetables is negatively correlated with 
bladder cancer, the underlying mechanisms of persistence of cancer are 
still unclear. 
The treatment of bladder cancer is highly costly, and there is an 
immediate need for developing novel potential therapeutic targets and 
pathways [127]. Earlier studies have demonstrated that the abnormal 
composition of fecal microbiota and disrupted gut epithelial barriers 
induce bladder cancer [127]. He et al. [127] have investigated the gut 
microbiome of patients with bladder cancer to find a potential thera-
peutic option. In their study, the Prevotella and Clostridium cluster XI 
rates were remarkably lower in patients with bladder cancer than the 
healthy individuals [127]. Up to 90% of SCFAs are absorbed from the 
colonic lumen and partly used by colonic epithelial cells that can be 
transferred to circulation and/or excreted in feces [128]. Hence, pro-
tective influences by SCFAs are seen in intestinal mucosa and extended 
to other parts of the body in the host. Clostridium cluster XI is known to 
produce SCFAs [129]. Prevotella is positively correlated with the con-
sumption of dietary fiber and fermentation of complex polysaccharides 
[130]. 
Meanwhile, SCFAs (especially butyric acid) were reduced in cancer 
patients [131]. Butyrate can also sensitize bladder cancer cells to 
anti-cancer drugs in vitro [132]. The reduced concentrations of butyrate 
in bladder cancer patients might reduce the proliferation and growth of 
IECs and reduce their negative effect on bladder cancer [127]. Never-
theless, the current study is of a relatively small number of cases in all 
stages, reflecting the low incidence of bladder cancer, so that larger 
sample sizes will be needed to further prove these findings. According to 
the studies, fruit intake is positively correlated with the numbers of 
Prevotella and the amount of butyrate [127]. Therefore, insufficient fruit 
intake might slightly lead to alterations in gut microbiota and SCFAs in 
patients with bladder cancer. 
5.3. Breast cancer 
Breast cancer is the most common malignant disorder among female 
populations, affecting 2.4 million cases with more than 500,000 deaths 
worldwide [133]. In 2015, 3.4 million breast cancer cases survived in 
the United States, and this frequency seems to be increasing [134–136]. 
The survival rate of breast cancer patients at least five years of diagnosis 
is about 90% [134], and this disorder is currently considered a chronic 
disease [137,138], which enables the improved endurance of survivors 
[134]. Nevertheless, a high-fat and high-sugar diet low in fiber and 
Fig. 3. The routes that butyrate inhibits the development of colorectal cancer. Butyrate could diminish the expression of Neuropilin 1 (NRP1) by suppressing the 
transactivation of Sp1 to inhibit the angiogenesis, metastasis, and survival of colorectal cancer cells, and butyrate could trigger the colorectal cancer cells apoptosis 
by activating the signaling of Wnt. Furthermore, butyrate could restrict the proliferation of cells, cell invasion, colony formation as well as activation of cell apoptosis 
in colorectal cancer cells via upregulating the miR-203, bax P21waf1 expression, and activation of the expression of endocan. Interestingly, SCFA butyrate could 
enhance Wnt expression, which attach to its receptor Fzd to induce Wnt signaling pathway. Hence, Fzd stimulates LRP5/LRP6/Dvl complex, which phosphates GSK- 
3beta that diminishes the beta-catenin degradation, resulting in accumulation of beta-catenin. When beta-catenin attaches to p300 protein, it causes apoptosis. Also, 
butyrate could enhance p57 levels by suppressing the c-Myc formation, which diminishes the miR-17-92a. Overall, the interplays between butyrate, NRP-1, endocan, 
Wnt, bax, P21waf1, miR-92a as well as miR-203 relate to the pro-apoptosis and anti-proliferation activity of butyrate in colorectal cancer cells. 
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minimum activity increases the risk of breast cancer [134]. Diet is 
crucially important in the interplay between the gut microbiome and 
estrogen metabolism, thereby affecting breast cancer metastasis and 
recurrence [134]. The typical American diet increases the growth of 
unhealthy bacteria with high levels of β-glucuronidase [134]. This 
enzyme conjugates estrogen and returns it to the bloodstream, thereby 
increasing its accessibility to drive estrogen-responsive cancers [134]. 
This diet reduces the generation of SCFAs, including propionate, buty-
rate, and acetate, which can inhibit “leaky gut syndrome” [134]. This 
syndrome increases the flow of harmful inflammatory outputs into the 
bloodstream, leading to breast cancer recurrence and progress [134]. 
Inflammatory proteins increase insulin resistance and leptin levels, 
which are involved in the modulation of carcinogenesis [139]. Binding 
of insulin molecules to steroid hormone-binding globulin (SHBG), in-
creases estrogen concentrations and accessibility, thereby contributing 
to breast carcinogenesis [140,141]. Reduced adiponectin levels 
contribute to insulin resistance and enhanced levels of insulin-like 
growth factor 1 (IGF-1), which can provoke cell proliferation [140]. 
On the contrary, a high-fiber diet leads to enhancing “healthy” 
microbiota [134]. Reduced β-glucuronidase activity reduces estrogen 
levels and elevates SGBH besides the fecal excretion of estrogen [134]. 
Following an increase in SCFAs, the colonic mucosa is preserved from 
inflammation, leaky gut syndrome, and cancer development [140,142, 
143]. Estrogen molecules are conjugated in the liver and secreted into 
the digestive system; they are then deconjugated by microbial β-glucu-
ronidase and reabsorbed as free estrogen in the circulatory system 
[134]. Several bacterial species contribute to this process; nevertheless, 
those with the ability to generate high levels of β-glucuronidase remain 
controversial [134]. Bacteroidetes and Firmicutes are predominant bac-
teria that contribute to the metabolism of polyphenols and fiber [134]. 
Researchers have reported different results on the effect of these phyla 
on obesity (a remarkable risk factor for breast cancer) [144–147]. 
Leaky gut syndrome and the subsequent inflammation may decrease 
by the intake of a high-fiber diet, leading to intestinal alkaline phos-
phatase and SCFAs production [148]. Intestinal alkaline phosphatase is 
essential for maintaining the integrity of intestinal endothelia 
[149–151]. In addition to SCFAs, gut alkaline phosphatase reinforces the 
colonic mucosa’s tight junction, thereby reducing the leakage of path-
ogenic bacteria and their carcinogenic effect [149–151]. The gut 
microbiota may enhance chronic inflammation by affecting 
self-proliferation and programmed cell death [152,153]. 
A subset of bacteria in gut microbiota control the genetic capability 
of estrogen metabolism: the estrobolome [134]. These bacteria use fiber 
as their main energy source [134]. Following the consumption of a diet 
high in fiber, the estrobolome promotes estrogen metabolism and sub-
sequently its removal from the body [134]. As about 70% of breast 
cancer cases are fueled by estrogen, a high-fiber diet eliminates estro-
gen, reducing breast cancer cells’ availability [134]. The “common-
sense” recommendation for breast cancer patients to consume dietary 
fiber leads to reduced inflammation [134]. The prolonged intake of fiber 
and polyphenols enhances the breast cancer survival rate [138,154]. 
Deregulation of epigenetic mechanisms, including post-translational 
histone modifications, has been indicated in women’s breast carcino-
genesis owing to the silencing of essential genes involved in tumor 
suppression [155]. Contrary to genetic alterations, epigenetic alter-
ations are thought to be reversed and have been evaluated for their 
potential in cancer treatment [156]. Bioactive dietary ingredients with 
anticancer effects can modulate DNA methylation and histone acetyla-
tion [157,158]. Reactivation of epigenetically silenced genes by food 
ingredients could be employed for cancer control [159]. As a dietary 
Fig. 4. The schematic representation of acetate, propionate and butyrate production.  
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HDACi, Butyrate is of great significance because of its anticancer effect 
and has been employed in phase I clinical trials for cancer treatment 
[160–162]. This SFCA is formed through the fermentation of dietary 
fiber by gut microbiota [163]. Butyrate is considered a promising 
approach for the management of breast cancer [164,165]. Various 
studies have indicated that butyrate limits the proliferation of breast 
cancer cell lines by functioning as an HDACi and stimulating the for-
mation of cyclin-dependent kinase inhibitor p21 [165–167]. 
The combination of retinoid and HDACi could potentially control 
cancer; however, few studies have indicated its efficiency in breast 
cancer [168]. Prior research showed that retinoic acid (RA) therapy 
increased the inhibitory properties of trichostatin (a synthetic HDACi) 
on human breast cancer cells [169]. More importantly, reactivation of 
RA receptor beta (RAR-β) by the synthetic HDACi enhanced the sus-
ceptibility of breast cancer cells to the inhibitory function of RA [169]. 
Despite the anticancer potential of HDACi combined with retinoid, few 
investigations have focused on the efficacy of such treatment, particu-
larly for breast cancer control [168]. Interestingly, although vitamin A 
does not block the proliferation of MCF-7 cells, it potentiates the hin-
drance of cell growth by butyrate [169,170]. This combinatorial effect 
may be attributed to the arrest of MCF-7 cells in the G2/M phase [169, 
170]. This enhances the efficacy of dietary HDACi butyrate along with 
retinoid in breast cancer control [171]. Nonetheless, the association 
between butyrate and vitamin A does not exert any combinatorial effect 
on hindering the proliferation of estrogen receptor-negative 
MDA-MB-231 breast cancer cells [171]. This implies that the breast 
cancer type should be taken into consideration when considering the 
co-administration of butyrate and retinoids for cancer treatment. 
5.4. Gastric cancer 
Gastric adenocarcinoma is the third common cause of cancer- 
mediated mortality worldwide [172]. Previous studies have indicated 
that genetic and environmental factors and bacterial infections can lead 
to cancer [173,174]. H. pylori is the most critical risk factor associated 
with human gastric cancer [175]. Chronic inflammation triggered by 
H. pylori can disrupt the function and structure of the gastric epithelium 
[176]. Nevertheless, successfully eliminating H. pylori bacterium does 
not entirely hinder gastric carcinoma development, and only up to 1% of 
the infected patients face gastric cancer development [177–179]. These 
findings imply that other determinants can be involved in the carcino-
genesis of human gastric cancer, and further investigations are required 
to determine these factors. 
Similar to the findings on the contribution of SCFAs in maintaining 
the integrity of the intestinal barrier and microbiota balance, as well as 
the hindrance of cancer and inflammation, Hu et al. [172] indicated that 
pathways contributing to SCFAs formation in gastric cancer are 
depleted, suggesting the presence of a more inflammatory condition and 
dysbiotic bacterial communities in gastric cancer. In contrast to these 
results, two investigations using 16 s rRNA to determine the microbiota 
of gastric mucosa demonstrated the pathways related to the generation 
of SCFAs in gastric cancer patients [180,181]. Nevertheless, it should be 
noted that the current study is limited by relatively small sample size 
and, hence, further longitudinal studies with more significant numbers 
of subjects are required. This discrepancy can be explained by the dif-
ferences in sample type, study population, and methodology. Further 
metagenomic, metaproteomic, and metatranscriptomic investigations 
are needed to confirm these results. 
Sodium acetate is an SCFA commonly used in the food industry to 
flavor food agents control pH [182]. The cytotoxicity of sodium acetate 
has also been widely evaluated [182]. Reportedly, sodium acetate pro-
motes differentiation and apoptosis and impedes the growth of CRC cell 
lines [182]. The anti-cancer properties of acetate originate from its 
capability to trigger apoptosis or necrosis in CRC cells by mitochondria 
[183]. Prior investigations have also demonstrated that sodium acetate 
at 12.5 mM concentration induces gastric adenocarcinoma cell growth 
and viability in a dose-dependent manner [182]. 
Nevertheless, sodium acetate at concentrations > 12.5 mM impedes 
cell proliferation in a dose-dependent manner [182]. Besides, cells 
treated with sodium acetate for 24 h demonstrated increased expression 
of IL-8, IL-1b, and TNF-α, the effect of which has been confirmed in mice 
[182]. The cytotoxic influences of sodium acetate on colonic epithelial 
cells have been investigated extensively. Nevertheless, once introduced 
to the human body through oral administration, organs such as the 
stomach can be exposed to sodium acetate; hence, the biological toxicity 
of sodium acetate cannot be limited to the colon and can extend to other 
parts. In this regard, Xia et al. [182] indicated the cytotoxicity of food 
with high doses of sodium acetate. Acetic acid has also been demon-
strated to inhibit the activity of NF-ĸB in Colo320DM cells [161]. In 
inflammatory conditions, acetate suppresses the migration of human 
neutrophils towards formyl- methionyl-leucyl-phenylalanine (f MLP) or 
C5a depending on GPR43 [184]. 
The Fas receptor (FasR)/Fas ligand (FasL) complex is a primary 
apoptotic route essential for the maintenance of cell colony, removal of 
malignant cells, and modulation of apoptosis [182]. Most human cancer 
cells harbor this complex [182]. The interplay between FasR and FasL on 
the surface of tumor cells leads to the initiation of apoptotic signaling, 
resulting in the stimulation of caspases, which in turn interacts with 
cytoplasmic signaling proteins that activate apoptosis [185]. Xia et al. 
[182] demonstrated the increased mRNA expression of FasL and FasR 
after the addition of 12.5–50 mM sodium acetate in a 
concentration-dependent manner. Subsets of caspases are triggered 
following Fas-initiated apoptosis [182]. Caspase-8 is the initial phase in 
the Fas-induced cascade of apoptosis [182]. Caspase-8 is activated 
following cleavage and activates other downstream caspases, thereby 
inducing apoptosis [186]. 
5.5. Liver cancer 
The occurrence of hepatocellular carcinoma (HCC) is clinically 
increasing [187], and both genetic and environmental determinants 
have been suggested in its initiation [187]. While susceptibility genes, 
ranging from traditional tumor suppressor genes to immune cell 
markers, have been identified, the potential environmental factors are 
not fully investigated [188]. Clearly, specific hepatotoxins such as 
aflatoxin, organochlorine compounds, and organochlorine compounds 
are markedly involved in the development of HCC similar to preneo-
plastic injuries linked with hepatitis C virus infection [189–191]. The 
involvement of gut microbes in the initiation and progression of HCC is 
yet to be identified [187]. Gut microbes are involved in the conversion 
of intestinal nitrates to nitirites and nitrosoamines which have been 
associated with CRC [192]. Besides, recent investigations have indicated 
the ability of Helicobacter hepaticus in inducing aflatoxin-promoted HCC 
in mice, which involves the formation of inflammatory and 
pro-proliferative cytokines [193]. These studies are consistent with the 
results of studies on humans where Helicobacter spp. could be isolated 
both from the intestine and liver [194,195]. Therefore, microbial 
metabolism of ingested food and byproducts and immune reactions to 
the bacteria contribute to liver cancer initiation and progression. 
Obesity and a high-fat diet are considered as primary risk factors for 
HCC progress; however, the exact molecular mechanisms remain un-
clear [196]. Alterations of intestinal microbiota may contribute to this 
pathogenetic pathway [196]. Yoshimoto et al. [197] investigated hep-
atocarcinogenesis in obese mice. They demonstrated that antibacterial 
drugs could reduce the risk of HCC development in treated mice by 
modulating dysbiosis and the subsequent secretion of 
pro-carcinogenetic and proinflammatory factors. Notably, fermentable 
non-digestible carbohydrates might also contribute to the control of 
tumor growth outside the digestive system [198]. Reportedly, oral 
administration of inulin-type fructans (ITF), as non-digestible carbohy-
drates, reduces the tumor size in breast or liver cancer animal models 
[199,200]. Saccharolytic bacteria can ferment inulin-type fructans, 
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thereby increasing SCFA production in the murine caecum [201]. As a 
prebiotic nutrient, ITF alters the activity and composition of the gut 
microbiome and controls the host immunity and metabolism [202–204]. 
Bindels et al. [198] showed the reduced proliferation of cancerous 
hepatocytes and reduced inflammation linked with cancer development 
following ITF administration to the leukemia mouse model. They also 
indicated the cyclic adenosine monophosphate (cAMP) level-dependent 
impact of propionate and the altered proliferation of cancer cells due to 
free fatty acid receptor 2 (FFA2) [198]. These results confirm the role of 
gut microbiota in controlling cancer progression. The human gut 
microbiota could affect the progression of BaF3 cells by inducing 
metabolomics alterations [198]. Bindels et al. [198] hypothesized that 
the increased concentration of metabolites derived from gut microbiota 
following ITF administration could pose a protective effect. Propionate 
has all of these requirements as it is generated in the portal vein of rats 
fed with ITF and is majorly taken up by the liver [192,205]. Bindels et al. 
[198] showed the increased levels of propionate in the portal blood of 
the BaF3-ITF mice. Notably, butyrate and propionate levels reduced 
following cancer [198]. This could be due to the alterations in the 
structure and composition of gut microbiota or the reduced food con-
sumption at the end of the therapy, which might have reduced the 
substrate supply. 
Dietary fiber-derived SCFAs may also affect extraintestinal cancer 
cell growth; they elevate the portal propionate concentrations to hinder 
the proliferation of cancerous hepatic cells [198]. Interestingly, a vali-
dated in vivo study indicated that pectin alleviates NAFLD (non-alco-
holic fatty liver disease) by SCFAs [206]. In contrast, diets supplemented 
with soluble fiber led to icteric HCC in dysbiotic mice [207]. The sup-
pression of gut fermentation and inhibition of dietary fiber hindered 
HCC [207]. Pharmacologic hindrance of fermentation or excluding 
fermenting bacteria significantly decreases the rate of intestinal SCFAs 
and inhibits HCC [207]. 
Gut microbiota has been linked with hepatocarcinogenesis due to 
hepatic inflammation via activating toll-like receptor 4 (TLR4) or 
forming cytotoxic secondary bile acids [208,209]. Singh et al. [210] 
indicated that disruption of microbiota hemostasis, dysmetabolism of 
SCFAs and bile acid, and hepatic inflammation could lead to HCC 
development. Several works have presented the anti-tumorigenic 
properties of SCFAs and inulin [210]. Nevertheless, they hypothesized 
that the formation of high butyrate levels following cholemia, dysbiosis, 
and inflammation might instead form a tumor-inducing condition that 
could prevail over its beneficial properties [210]. This hypothesis agrees 
with the ‘‘butyrate paradox,’’ which asserts that the capability of buty-
rate to provoke or prevent cell proliferation depends on time, cell-type, 
and concentration [211]. The concentrations of SCFA that exceed the 
threshold and can be tolerated by the host have been indicated to pro-
mote colonic inflammation and tumorigenesis, induce urethritis and 
hydronephrosis, and promote obesity by aggravating hyperphagia and 
hepatic lipogenesis [210]. Janssen et al. [212] demonstrated that the 
consumption of dietary guar gum (a soluble fiber containing galactose 
[1,6-linked] and mannose [b1,4-linked]) for over 4 months protected 
mice from diet-induced obesity; however, it promoted the inflammation 
of the liver due to elevated plasma levels of total bile acid (TBA) and 
impaired circulation within the liver. Although Janssen et al. [212] did 
not observe HCC, their findings confirm that the consumption of soluble 
fiber might not be useful to the host liver in case functional gut bacteria 
are absent. 
5.6. Lung cancer 
Human lung cancer is one of the most fatal disorders with the fastest- 
growing rate of mortality and morbidity in the world [213]. The asso-
ciation between lung cancer and gut microbiota has been studied [213], 
and increased numbers of Enterococcus spp. and reduced numbers of 
Actinobacteria and Bifidobacterium have been linked with lung cancer 
[213]. Besides, disruption of the normal activity of gut microbiota 
affects lung cancer progression [214]. In another study, reduced 
numbers of Enterobacter, Dialister, Fecalibacterium, Kluyvera, Escher-
ichia–Shigella, and higher Fusobacterium numbers Bacteroides, and 
Veillonella were found in lung cancer patients compared to the control 
[215]. The association between relative frequency of the bacteria as 
mentioned above and systemic inflammation-related markers, such as 
neutrophil-to-lymphocyte ratio (NLR), prognostic nutritional index, 
platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio 
(LMR), were investigated [216]. The findings demonstrated that 
Enterobacter and Escherichia–Shigella, were positively correlated with 
serum levels of NLR, while Dialister was negatively correlated with 
serum levels of NLR and PLR [216]. Furthermore, Dialister was also 
associated with serum contents of IL-12 and cytotoxic T-lymphocyte 
antigen 4 (CTLA-4) [215]. Alterations in gut microbiota have been 
correlated with the development of immune-mediated diarrhea in pa-
tients with lung cancer following treatment with antibodies against 
anti-PD-1 (anti-programed cell death protein-1) [213]. In patients 
without diarrhea, Bacteroides, Phascolarctobacterium, and Para-
bacteroides were more abundant, while Veillonella was less abundant 
[217]. 
It is well defined that gut microbiota affects human gastrointestinal 
cancer [218]. It has also been proposed that gut microbiota mediate 
extraintestinal cancers [219]. Several investigations have found an as-
sociation between gut microbiota and lung cancer [220]. Zhang et al. 
[221] demonstrated that in lung cancer patients Fusobacteria, Bacter-
oidetes, Spirochaetes, Cyanobacteria, and Lentisphaerae were more abun-
dant, while Verrucomicrobia and Firmicutes were less abundant compared 
to the healthy group. According to their study, eight predominant bac-
terial genera were markedly diverse between the two groups [221]. 
Investigations have implied that patients with lung cancer have diverse 
gut microbiota and, more importantly, these microbiota influence the 
therapeutic prognosis of human lung cancer [220]. According to a study, 
early resistance to immune checkpoint inhibitors could be due to gut 
microbiota’s abnormal structure and composition [222]. Since Akker-
mansia muciniphila levels are often reduced in patients with lung cancer, 
supplementation with this bacterium could enhance the immune 
checkpoint inhibitor responses [222]. Another investigation on the lung 
cancer mouse model reported that the commensal bacteria are involved 
in the anti-lung cancer reaction, and simultaneous treatment with pro-
biotics promotes the pro-apoptotic and anti-growth properties of 
cisplatin [220]. 
In a recent study, sodium butyrate treatment upregulated miR-3935, 
which in turn inhibited the growth and migration of a549 cells [223]. 
Microbiota-derived SCFAs influence colon cancer progression by dys-
regulating Bax, p21, Bcl-2, and regulating histone hyperacetylation 
[224,225]. Furthermore, sodium butyrate could also inhibit lung and 
prostate cancer growth by modulating p21 expression [226]. Most in-
vestigations on SCFAs have focused on butyrate, while the function of 
propionate in lung cancer is not well established [226]; however, one 
study focused on the association between lung cancer and propionate 
and provided information concerning the function of propionate in lung 
cancer treatment [225,227]. According to their study, although propi-
onate inhibited cell growth and induced apoptosis in CRC cell lines, it 
could also show anticancer properties for lung cancer by activating cell 
apoptosis and cell cycle arrest by reducing the Survivin expression and 
increasing p21 expression [226]. Therefore, despite facing several 
problems associated with SCFAs application for lung cancer, treatment, 
dietary and microbiome-derived SCFAs may be beneficial; nevertheless, 
in vivo works are required to confirm the efficacy of sodium propionate. 
5.7. Other cancers 
Pancreatic ductal adenocarcinoma (PDAC) is a fatal disorder with a 
mortality rate of 94% has been reported within five years of diagnosis 
[228]. PDAC is the fourth most common human cancer. Globally, in 
2018 alone, 458, 918 PDAC cases were reported, among which 432,242 
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cases died [229]. The rate of PDAC cases has increased and is estimated 
to grow even more sharply in the future [230,231]. The association 
between microbiota and PDAC was first suggested by identifying 
H. pylori in patients with pancreatitis [232]. This was followed by 
findings regarding the relationship between the fecal, pancreas, gut, oral 
microbiota, the mycobiome, and pancreatic cancer [232–235]. 
Several works have suggested alterations in the proportions, di-
versity, and dominant constituents of the microbiota (Neisseria Por-
phyromonas, Streptococcus, Actinomycetes, Bacteroides Fusobacterium and 
Bifidobacteria) might be linked with PDAC initiation and progression 
[236–239]. Acetate can alleviate pancreatitis, thereby protecting 
against a risk factor of PDAC [240]. Acetic acid triggers the epigenetic 
reprogramming of mesenchymal stem cells to cancer-related fibroblasts 
that improve the invasiveness of PDAC cells [241]. At a concentration of 
2 mM, butyric acid can diminish the growth of cultured PDAC cells 
(HPAF and Panc-1 cells) and activate differentiation towards a secretory 
phenotype specified by ultrastructural alterations [242]. Besides, a hy-
aluronic acid conjugate of butyrate was cytostatic in a cultured PDAC 
cell line [243]. A branched-chain SCFA (valproic acid) was also cyto-
static in PDAC cells when administered in combination with 5-fluoro-
uracil, implying similar traits for bacterial SCFAs [244]. In the 
PDAC-related oncobiome, butyrate-forming microbes reduced, 
implying that the abovementioned beneficial impacts of SCFAs are 
inhibited in this cancer type [237]. 
Prostate cancer is the second leading cause of human death in the 
United States, approximately 20% in men [245]. The lifetime risk for 
human prostate cancer is approximately 16%, with 276,000 new cases 
in 2018 [246]. Common therapy for human prostate cancer is mainly 
based on androgens; nevertheless, this does not cover other risk factors 
for human prostate cancer, including environmental factors, inflam-
matory markers, and microbial infections [247]. One of the first in-
vestigations on the link between commensal bacteria and the prostate 
was carried out by Cavarretta and his colleagues [248]. Banerjee et al. 
[249] addressed the relationship between microbiota and prostate 
cancer more comprehensively. The employed microarray metagenomic 
analysis of formalin-fixed tissue to identify bacterial, viral, and fungal 
signature of 50 prostate cancer patients and 15 patients with benign 
prostatic hyperplasia [249]. Most isolated bacteria were Gram-negative, 
including Firmicutes, Proteobacteria, Bacteroidetes, and Actinobacteria 
[249]. A hierarchical evaluation indicated that particular clusters of 
bacterial signatures are correlated with the grade of human prostate 
cancer [249]. Additionally, Propionibacterium acnes has been demon-
strated to be involved in human prostate cancer progression [250,251]. 
Recently, the pro-carcinogenic properties of bacterial products have 
been implicated. For instance, in breast cancer, bacterial peptides have 
been attributed to tumor cell angiogenesis and invasion [252]. This 
could be a new field of investigation, and the bacterial metabolites in the 
prostate should be thoroughly studied (Tables 1 and 2). 
Table 1 
Short-chain fatty acids and their bacterial producers.  
Metabolite Bacterial producer Ref. 
Butyrate Coprococcus catus, Coprococcus comes, Anaerostipes 
spp., Coprococcus eutactus, Eubacterium hallii, 
Eubacterium rectal, Roseburia spp., Faecalibacterium 
prausnitzii, Clostridium butyricum, Ruminococcus, 
Anaerostipes spp., Coprococcus catus, 
[274,275, 
276,277] 
Propionate Dialister spp., Megasphaera elsdenii, Bacteroides spp. 
Phascolarctobacterium succinatutens, Coprococcus 
catus, Veillonella, Roseburia inulinivorans, 
Ruminococcus obeum, Salmonella spp. 
[274,275] 
Acetate Akkermansia muciniphila, Bacteroides spp., Prevotella 
spp. Bifidobacterium spp., Clostridium spp., 
Ruminococcus spp., Streptococcus spp., Blautia 




Short-chain fatty acids in various cancers.  





Butyrate Butyrate mediates the suppression of 
NF-κB, inhibits HDAC, induces WNT/ 
beta-catenin activity and apoptosis, 
activates MAPK signaling pathway by 
the upregulation of GADD153 or 
activation or phosphorylation of JNK. 
[279] 
Acetate Acetate triggers apoptosis in colorectal 
cancer cells activates cathepsin D 
release and induces lysosomal 
membrane permeabilization. In return, 
cathepsin D protects colorectal cancer 




Propionate Propionate reduces the expression of 
PRMT1, induces apoptosis in colon 





Butyrate Sodium butyrate triggers AMPK/ 
mTOR pathway-activated autophagy 
and reactive oxygen species 
overproduction through the miR- 
139–5p/Bmi-1 route. 
[283] 
Butyrate inhibits cell growth and 
triggers apoptosis in bladder cancer 
cell lines. 
Acetate Acetate shows inhibitory impacts on 
the invasion and migration of T24 and 




Acetate Ethyl acetate shows an anti- 
proliferation impact on breast cancer 
cells in a ROS-dependent manner. 
[285] 
Butyrate Sodium butyrate induces apoptosis 
following increased ROS levels, 
increases caspase activity, and 
decreases mitochondrial membrane 
potential in both normal breast and 






Butyrate and propionate regulate the 
cell cycle, apoptosis, glucose-6- 
phosphate dehydrogenase activity, and 
glutathione availability in the Kato III 
human gastric cell lines. Both butyrate 
and propionate reduced the numbers of 
cancer cells in G0/G1 phase and 
elevated the numbers of cells in the G2- 
M phase of the cell cycle. 
[287] 
Butyrate Butyrate induces the increased 
numbers of cells in the S phase of the 
cell cycle. 
[287] 
Acetate Acetic acid induces lipid peroxidation 
following oxidative stress resulting in 
gastric epithelial cell apoptosis. 
[288] 
Liver cancer Butyrate Butyrate hinders cell proliferation and 
triggers apoptosis in both Hep3B and 
HepG2 cells. Long-term exposure to 
butyrate increases hepatocyte growth 
and fibrosis in the liver. Butyrate 
influences the proliferation of liver 
cells. 
[210] 
Acetate Protein kinase C (PKC) α promotes the 
activation of MEK/ERK for 12-O 
tetradecanoylphorbol-13-acetate 
-induced inhibition of HepG2. 
[289] 
Lung cancer Butyrate Sodium butyrate increases the 
expression levels of P-gp and STAT3. It 
also increases STAT3 phosphorylation 
and improves mRNA stability of 
ABCB1 in human lung cancer cells. 
[290] 
Propionate Propionate acts as an anticancer 
component for lung cancer therapy, by 
triggering cell apoptosis and cell cycle 
arrest by up-and down-regulation of 
[291] 
(continued on next page) 
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6. Clinical studies 
Investigations of different types of cancer [222,253,254] have pro-
posed that the gut microbiome profile is a potential agent correlated 
with the efficiency of immune checkpoint inhibitors. Various preclinical 
and clinical investigations have established a relationship between the 
gut microbiome and the efficiency of immune checkpoint inhibitors, but 
how this relationship roles in the tumor microenvironment continues 
unclear. The SCFAs have been validated to modulate immune system 
response (Table 3) [85]. Recently, in a study, Yu et al. [255] investigated 
the relationship between fecal butyrate, acetate, and propionate con-
centration and NRP1 (Neuropilin 1) expression in human colonic mu-
cosa. In the current study, adenomas showed extensive, weaker staining 
for NRP-1, which contrastingly correlated positively with butyrate level. 
Besides, in a study by Lewis et al. [256], they found that bowel transit 
rate is a determinant of stool SCFA concentration, including butyrate 
and distal colonic pH. In summary, this may explain the inter-relations 
between colonic cancer, dietary fiber intake, stool output, and stool pH. 
Nomura et al. [85] found that high concentrations of fecal or plasma 
SCFAs were mediated to respond to PD-1i treatment and longer 
progression-free survival. SCFAs exhibit immunomodulatory activities 
in the host, affecting CD4+ T lymphocytes as well as antigen-presenting 
cells. Butyrate has been shown to induce FOXP3+ CD4+ Treg differ-
entiation [257,258]. Nevertheless, a recent report found that butyrate 
and other SCFAs increase IFNγ and granzyme B expression in CD8+
cytotoxic T cells and IL-17–secreting CD8+ T cells [259]. Another 
function of SCFAs is inhibition of HDACs; in this regard, it has been 
found that HDAC inhibition was found to upregulate PD-1 ligands in 
melanoma cells, increase the immunotherapy reactions, suppress 
apoptosis of CD4+ T lymphocytes within tumor parts, upregulate the 
antitumor immune response, and inhibition of tumor cell proliferation 
[85,259]. 
Interestingly, Harig et al. [260] were the first to treat diversion colitis 
successfully with SCFA irrigation (acetate 60 mM, propionate 30 mM, 
n-butyrate 40 mM). In distal ulcerative colitis, impaired mucosal 
oxidation of SCFAs has been described despite their luminal abundance 
[260]. Pilot studies using either the SCFA mixture or butyrate mono-
therapy have yielded promising results [260]. Nevertheless, extended 
confirmatory studies with a larger sample size have not yet been per-
formed. Preliminary data are also available for the administration of 
SCFA in pouchitis and radiation proctitis [260]. In summary, SCFA 
topical therapy seems to be a promising option in distinct forms of IBD; 
nevertheless, the usual administration of SCFAs cannot be recom-
mended until their efficacy has been confirmed in larger trials. 
A Pilot Randomized study evaluated butyrate irrigation before 
ileostomy closure on the colonic mucosa in rectal cancer patients 
(BUTYCLO) has started [261]. The influences of butyrate irrigations 
before ileostomy closure on colonic mucosa will be studied in 45 rectal 
cancer patients. In their study, short-term outcomes, colonic microbiota 
composition, and functional outcomes will be evaluated after ileostomy 
reversal [261]. All in all, it seems that the fecal SCFA concentrations are 
associated with the efficacy of immune checkpoint inhibitor therapy. 
SCFAs fecal analyses are entirely noninvasive; they may be suitable for 
regular monitoring of cases with cancer. Clarification of the mechanisms 
in which SCFA modulation immune response could enable discovering 
innovative targets to promote immune checkpoint inhibitor efficacy in 
cancer cases. Further studies as validation investigations are required to 
confirm the recent findings. 
Table 2 (continued ) 
Cancer Short chain 
fatty acid 
Function Ref. 




Butyrate Sodium butyrate hinders the 
expression of b4 Integrin, reduces the 
cell surface expression of b4, and 
hinders the invasion of pancreatic 
cancer. 
[292] 
Acetate Medroxyprogesterone acetate blocks 
the proliferation of pancreatic 
carcinoma cell lines (Capan-2, AsPC-1, 
and MiaPaCa-2) and leads to cell 




Butyrate Sodium butyrate reduces the 
expression of androgen receptor (AR) 
in LNCaP and LAPC4 prostate cancer 
cells, with a significant role in the 
initiation and progression of prostate 
cancer. 
[294] 
Acetate Acetate increases the need for these 
lipids in cancers with elevated cell 
turnover. 
[295] 
Propionate Employment of propionates (e.g., 
naproxen and ibuprofen) reduces the 



















Acetate Decreased Fecal – [297] 
Colorectal 
cancer 
Propionate Decreased Fecal – [297] 
Solid cancer 
tumors 
Butyrate Decreased in non-responder 
than responder to anti-PD1 
therapy 
Fecal and plasma The results of this cohort study suggest that fecal SCFA concentrations are 




Acetate Decreased in non-responder 
than responder to anti-PD1 
therapy 
Fecal and plasma – [85] 
Solid cancer 
tumors 
Propionate Decreased in non-responder 
than responder to anti-PD1 
therapy 
Fecal and plasma – [85] 
Melanoma Butyrate – In vitro and in 
vivo 
This investigation revealed that systemic microbial SCFA modulates anti-CTLA- 
4-provoke immune responses and its antitumor potency. 
[273] 
Breast cancer Butyrate – Cell line The finding of the investigation for the first time demonstrated that butyrate is a 
BCRP substrate. It is crucial in the setting of the high concentration of BCRP 
production in the colon and the anticarcinogenic, anti-inflammatory capacity of 
butyrate at that level. 
[298]  
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7. Roles of microbiota-derived short-chain fatty acids in 
response to cancer immunotherapy 
Using advanced high-throughput techniques, it has been indicated 
that microbiota affects oncogenesis and immunotherapy [262]. The 
commensal bacteria can negatively or positively affect tumor occurrence 
and progression [263]. Particular bacteria generate toxins or tumori-
genic components that lead to immunosuppressive or inflammatory 
responses that favor oncogenesis [262]. On the contrary, gut microbiota 
may tackle cancer by boosting anti-tumor immunity [263]. Further-
more, the commensal bacteria impair the efficacy of anti-cancer treat-
ment and toxicity by altering the local and systemic immune responses 
[264]. Analysis of microbial metabolites, including SCFAs, and impair-
ment of gut microbiota balance regarding their effects on immune re-
sponses will improve the knowledge of several common etiology 
diseases [265]. SCFAs, mainly acetate, butyrate, and propionate, are 
present in certain concentrations, and their proportions can alter 
depending on age, diet, and disease [265]. SCFA concentrations are 
mainly modulated by the proportion of gut microbiota, and dysbiosis 
can imbalance the generated SCFAs [265]. It has also been established 
that SCFAs impede the activity of HDAC, which is mainly involved in the 
process of deacetylation and histone crotonylation [265]. These prop-
erties of SCFAs potentiate their immunomodulatory effects and support 
the anti/pro-inflammatory hemostasis [265]. SCFAs have local func-
tions in the intestines colonized by gut bacteria, have an impact on gut 
immune cells, and regulate the immune system by multi-protein 
inflammasome complexes [265]. SCFAs are essential for immune mod-
ulation [266]. Butyrate has systemic anti-inflammatory functions by 
altering adhesion, migration, and cytokine expression of immune cells 
and affecting cellular processes such as propagation, activation, and 
apoptosis [267]. 
Notably, among SCFAs, butyrate is frequently associated with 
immune-modulation, mainly through the induction of T-reg cells [268]. 
Studies recommend that the structure of human intestinal microbiota is 
related to anti-tumor effectiveness in patients with metastatic melanoma 
treated with anti- PD-1 and anti-CTLA-4 monoclonal antibodies [253, 
269,270]. Also, the gut microbiome composition seems to be correlated 
with the risk of increasing anti-CTLA-4-stimulated colitis in patients 
with metastatic melanoma [270,271]. These recent studies indicate the 
connection between the presence of certain bacteria and clinical 
response and/or toxicities. Importantly, gut microbiota with high 
numbers of Faecalibacterium and other Firmicutes was linked with a good 
clinical reaction to anti-PD-1, ipilimumab, and ipilimumab/anti-PD-1 
treatment in human melanoma patients [270,272]. Based on these 
studies, it seems that Faecalibacterium is majorly mediated to clinical 
reactions in metastatic melanoma patients treated with immune 
checkpoints [273]. 
Nevertheless, few studies have indicated the way that gut micro-
biome composition could affect a tumor. Regarding the previous find-
ings on the relationship between gut microbiota structure and clinical 
response and the impact of SCFAs on the immune responses, Coutzac 
et al. [273] investigated the induction of anti-cancer (metastatic mela-
noma) response due to systemic bacterial SCFA and anti-CTLA-4 
blockade. This study demonstrated that systemic bacterial SCFAs regu-
late anti-CTLA-4-stimulated immune responses and their anti-tumor 
effectiveness [273]. Overall, they indicated that the systemic butyrate 
(and propionate) constrain the anti-tumor properties of anti-CTLA-4 
[273]. These results suggest an association between the structure of 
human gut bacteria and the clinical reactions to ipilimumab through 
microbiota-derived metabolites. Overall, as these microbial SCFAs have 
various roles in the immune system in different situations, these me-
tabolites may be involved in immunotherapy against cancers of the in-
testinal and extraintestinal tract. Further works are needed to define the 
exact roles and mechanisms of bacterial spp. (In particular metabolite 
products) to improve cancer treatment approaches. 
8. Conclusion 
It has been indicated that microbiota can alter the host immune re-
sponses, inflammation, and metabolic pathways, thereby playing a 
central role in cancer occurrence and progression. Similarly, the SCFAs 
generated by gut microbiota have crucial roles in cancer occurrence and 
progression. The alternations in gut structure change SCFA levels, 
thereby affecting HDAC, cell adhesion, cytokine production, chemo-
taxis, immune cell recruitment, and apoptosis. Therefore, studies in this 
field can help us combat cancer. Although many studies have been 
conducted on SCFAs and their association with cancer, most studies 
have focused on CRC. 
Functional foods like prebiotics and probiotics have beneficial in-
fluences in controlling and preventing cancer in preclinical and animal 
models. As a result, these agents have attracted attention for playing a 
role in preventing cancer development. In this regard, it has been found 
the immunomodulatory influences of SCFAs generated by probiotics, 
but the processes of their activities still need much investigation. The 
administration of probiotic bacteria to treat and prevent intestinal 
dysbiosis that can cause SCFAs formation seems to be crucial for further 
study. Microbiota-derived SCFAs seem to act synergistically on anti-
tumor approaches, such as drugs to control immune reactions to cancer 
cells by dampening stimulation of inflammatory cytokines and activa-
tion of Tregs that have a crucial activity in controlling the tumor cells. In 
summary, further studies should focus on the mediation of SCFAs in 
other GI cancers to determine their exact role in cancer development and 
treatment. Finally, pinpointing a particular pathway involved in SCFA- 
mediated immune-modulatory effects is an attractive area of research 
that could enable the detection of targets to improve cancer therapy. 
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N. Sacchi, Endogenous reactivation of the RARβ2 tumor suppressor gene 
epigenetically silenced in breast cancer, Cancer Res. 62 (9) (2002) 2455–2461. 
[170] N.P. Mongan, L.J. Gudas, Valproic acid, in combination with all-trans retinoic 
acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARβ2 in breast 
cancer cells, Mol. Cancer Ther. 4 (3) (2005) 477–486. 
[171] F. Andrade, M. Nagamine, A.D. Conti, L. Chaible, C. Fontelles, A. Jordão Junior, 
H. Vannucchi, M. Dagli, B. Bassoli, F.S. Moreno, Efficacy of the dietary histone 
deacetylase inhibitor butyrate alone or in combination with vitamin A against 
proliferation of MCF-7 human breast cancer cells, Braz. J. Med. Biol. Res. 45 (9) 
(2012) 841–850. 
[172] Y.-L. Hu, W. Pang, Y. Huang, Y. Zhang, C.-J. Zhang, The gastric microbiome is 
perturbed in advanced gastric adenocarcinoma identified through shotgun 
metagenomics, Front. Cell. Infect. Microbiol. 8 (2018), 433-433. 
[173] C.L. Sears, W.S. Garrett, Microbes, microbiota, and colon cancer, Cell Host 
Microbe 15 (3) (2014) 317–328. 
[174] J. Chen, J.C. Domingue, C.L. Sears, Microbiota dysbiosis in select human cancers: 
evidence of association and causality, Semin. Immunol. 32 (2017) 25–34. 
R. Mirzaei et al.                                                                                                                                                                                                                                 
Biomedicine & Pharmacotherapy 139 (2021) 111619
16
[175] D.B. Polk, R.M. Peek Jr., Helicobacter pylori: gastric cancer and beyond, Nat. Rev. 
Cancer 10 (6) (2010) 403–414. 
[176] M. Amieva, R.M. Peek Jr., Pathobiology of Helicobacter pylori-induced gastric 
cancer, Gastroenterology 150 (1) (2016) 64–78. 
[177] J.L. Ma, L. Zhang, L.M. Brown, J.Y. Li, L. Shen, K.F. Pan, W.D. Liu, Y. Hu, Z. 
X. Han, S. Crystal-Mansour, D. Pee, W.J. Blot, J.F. Fraumeni Jr., W.C. You, M. 
H. Gail, Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments 
on gastric cancer incidence and mortality, J. Natl. Cancer Inst. 104 (6) (2012) 
488–492. 
[178] Y.C. Lee, T.H. Chiang, C.K. Chou, Y.K. Tu, W.C. Liao, M.S. Wu, D.Y. Graham, 
Association between Helicobacter pylori eradication and gastric cancer incidence: 
a systematic review and meta-analysis, Gastroenterology 150 (5) (2016) 
1113–1124, e5. 
[179] M.A. Shah, Gastric cancer: the gastric microbiota – bacterial diversity and 
implications, Nat. Rev. Gastroenterol. Hepatol. 14 (12) (2017) 692–693. 
[180] N. Castaño-Rodríguez, K.L. Goh, K.M. Fock, H.M. Mitchell, N.O. Kaakoush, 
Dysbiosis of the microbiome in gastric carcinogenesis, Sci. Rep. 7 (1) (2017) 
15957. 
[181] O.O. Coker, Z. Dai, Y. Nie, G. Zhao, L. Cao, G. Nakatsu, W.K. Wu, S.H. Wong, 
Z. Chen, J.J.Y. Sung, J. Yu, Mucosal microbiome dysbiosis in gastric 
carcinogenesis, Gut 67 (6) (2018) 1024–1032. 
[182] Y. Xia, X. Zhang, F. Jin, Q. Wang, R. Xiao, Z. Hao, Q. Gui, J. Sun, Apoptotic effect 
of sodium acetate on a human gastric adenocarcinoma epithelial cell line, Genet. 
Mol. Res. 15 (2016). 
[183] C. Marques, C.S.F. Oliveira, S. Alves, S. Chaves, O. Coutinho, M. Côrte-Real, 
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